A Single Human Papillomavirus Vaccine Dose Improves B Cell Memory in Previously Infected Subjects

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2016 Jul 18

PMID 27423190

Citations 28

Authors

Erin M Scherer

Robin A Smith

Daniel F Gallego

Joseph J Carter

Gregory C Wipf

Manuela Hoyos

Michael Stern

Tate Thurston

Nathan D Trinklein

Anna Wald

Denise A Galloway

Affiliations

Soon will be listed here.

Abstract

Although licensed human papillomavirus (HPV) vaccines are most efficacious in persons never infected with HPV, they also reduce infection and disease in previously infected subjects, indicating natural immunity is not entirely protective against HPV re-infection. The aim of this exploratory study was to examine the B cell memory elicited by HPV infection and evaluate whether vaccination merely boosts antibody (Ab) levels in previously infected subjects or also improves the quality of B cell memory. Toward this end, the memory B cells (Bmem) of five unvaccinated, HPV-seropositive subjects were isolated and characterized, and subject recall responses to a single HPV vaccine dose were analyzed. Vaccination boosted Ab levels 24- to 930-fold (median 77-fold) and Bmem numbers 3- to 27-fold (median 6-fold). In addition, Abs cloned from naturally elicited Bmem were generally non-neutralizing, whereas all those isolated following vaccination were neutralizing. Moreover, Ab and plasmablast responses indicative of memory recall responses were only observed in two subjects. These results suggest HPV vaccination augments both the magnitude and quality of natural immunity and demonstrate that sexually active persons could also benefit from HPV vaccination. This study may have important public policy implications, especially for the older 'catch-up' group within the vaccine's target population.

Citing Articles

ULACNet-301, OPTIMO protocol: optimizing HPV vaccination regimen for cancer prevention in children and adolescents living with HIV.

Pinto-Santini D, Jalil E, Fernandes G, Hilaire G, Kolevic L, Cabello R BMC Cancer. 2025; 25(1):151.

PMID: 39871186 PMC: 11771066. DOI: 10.1186/s12885-025-13551-z.

Time-resolved fluorescence (TRF) for total IgG and HPV16-specific antibody detection in first-void urine and serum: A comparative study.

Lipovac M, Teblick L, Bell M, Van Caesbroeck A, De Smet A, Van Keer S J Virol Methods. 2024; 329:115003.

PMID: 39069158 PMC: 11406150. DOI: 10.1016/j.jviromet.2024.115003.

HPV Vaccine Awareness, Past Behaviors, and Future Intentions Among a Diverse Sample of Fathers Aged 27 to 45 Years: A National Survey.

Quist K, Fontenot H, Zimet G, Lim E, Matsunaga M, Liebermann E Am J Mens Health. 2024; 18(3):15579883241258823.

PMID: 38879825 PMC: 11181892. DOI: 10.1177/15579883241258823.

Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials.

Whitworth H, Mounier-Jack S, Choi E, Gallagher K, Howard N, Kelly H Vaccine X. 2024; 19:100486.

PMID: 38873638 PMC: 11169951. DOI: 10.1016/j.jvacx.2024.100486.

Human Papillomavirus and Associated Cancers: A Review.

Jensen J, Becker G, Jackson J, Rysavy M Viruses. 2024; 16(5).

PMID: 38793561 PMC: 11125882. DOI: 10.3390/v16050680.

References

de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D . Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012; 13(6):607-15. DOI: 10.1016/S1470-2045(12)70137-7. View

Joura E, Giuliano A, Iversen O, Bouchard C, Mao C, Mehlsen J . A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372(8):711-23. DOI: 10.1056/NEJMoa1405044. View

Franz B, May Jr K, Dranoff G, Wucherpfennig K . Ex vivo characterization and isolation of rare memory B cells with antigen tetramers. Blood. 2011; 118(2):348-57. PMC: 3138687. DOI: 10.1182/blood-2011-03-341917. View

Priyamvada L, Cho A, Onlamoon N, Zheng N, Huang M, Kovalenkov Y . B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts. J Virol. 2016; 90(12):5574-85. PMC: 4886779. DOI: 10.1128/JVI.03203-15. View

Purtha W, Tedder T, Johnson S, Bhattacharya D, Diamond M . Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J Exp Med. 2011; 208(13):2599-606. PMC: 3244041. DOI: 10.1084/jem.20110740. View

de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

Buck C, Pastrana D, Lowy D, Schiller J . Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med. 2005; 119:445-62. DOI: 10.1385/1-59259-982-6:445. View

Tangye S, Good K . Human IgM+CD27+ B cells: memory B cells or "memory" B cells?. J Immunol. 2007; 179(1):13-9. DOI: 10.4049/jimmunol.179.1.13. View

Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760. View

10.

Wentzensen N, Rodriguez A, Viscidi R, Herrero R, Hildesheim A, Ghosh A . A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study. J Infect Dis. 2011; 204(1):94-102. PMC: 3130470. DOI: 10.1093/infdis/jir209. View

11.

Scherer E, Smith R, Simonich C, Niyonzima N, Carter J, Galloway D . Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog. 2014; 10(10):e1004461. PMC: 4199765. DOI: 10.1371/journal.ppat.1004461. View

12.

Wrammert J, Smith K, Miller J, Langley W, Kokko K, Larsen C . Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008; 453(7195):667-71. PMC: 2515609. DOI: 10.1038/nature06890. View

13.

Brochet X, Lefranc M, Giudicelli V . IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008; 36(Web Server issue):W503-8. PMC: 2447746. DOI: 10.1093/nar/gkn316. View

14.

Scherpenisse M, Schepp R, Mollers M, Meijer C, Berbers G, van der Klis F . Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013; 8(9):e74797. PMC: 3776846. DOI: 10.1371/journal.pone.0074797. View

15.

de Villiers E, Fauquet C, Broker T, Bernard H, Zur Hausen H . Classification of papillomaviruses. Virology. 2004; 324(1):17-27. DOI: 10.1016/j.virol.2004.03.033. View

16.

Chiu C, Wrammert J, Li G, McCausland M, Wilson P, Ahmed R . Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Ann N Y Acad Sci. 2013; 1283:13-21. DOI: 10.1111/nyas.12012. View

17.

Stanley M, Pinto L, Trimble C . Human papillomavirus vaccines--immune responses. Vaccine. 2012; 30 Suppl 5:F83-7. DOI: 10.1016/j.vaccine.2012.04.106. View

18.

Bernard H, Burk R, Chen Z, Van Doorslaer K, Zur Hausen H, de Villiers E . Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010; 401(1):70-9. PMC: 3400342. DOI: 10.1016/j.virol.2010.02.002. View

19.

Katzenellenbogen R, Carter J, Stern J, Butsch Kovacic M, Mehta P, Sauter S . Skin and mucosal human papillomavirus seroprevalence in persons with Fanconi Anemia. Clin Vaccine Immunol. 2015; 22(4):413-20. PMC: 4375352. DOI: 10.1128/CVI.00665-14. View

20.

Lavinder J, Wine Y, Giesecke C, Ippolito G, Horton A, Lungu O . Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A. 2014; 111(6):2259-64. PMC: 3926051. DOI: 10.1073/pnas.1317793111. View